Xortx Therapeutics INC. (XRTX) — SEC Filings

Latest SEC filings for Xortx Therapeutics INC.. Recent 6-K filing on Apr 21, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Xortx Therapeutics INC. on SEC EDGAR

Overview

Xortx Therapeutics INC. (XRTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 21, 2026: XORTX Therapeutics Inc. filed a Form 6-K on April 21, 2026, reporting information as a foreign issuer. The filing includes a press release as Exhibit 99.1. The company's mailing and business address is Suite 2400 - 745 Thurlow Street, Vancouver, A1 V6E 0C5.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 50 neutral. The dominant filing sentiment for Xortx Therapeutics INC. is neutral.

Filing Type Overview

Xortx Therapeutics INC. (XRTX) has filed 49 6-K, 1 20-F with the SEC between May 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

XORTX Therapeutics Files 6-K Report — 6-K · Apr 21, 2026 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on April 21, 2026, reporting information as a foreign issuer. The filing includes a press release as Exhibit 99.1. The
6-K Filing — 6-K · Apr 1, 2026
XORTX Therapeutics Files 6-K Report — 6-K · Mar 27, 2026 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on March 27, 2026, reporting information as of March 26, 2026. The filing includes a press release as an exhibit.
6-K Filing — 6-K · Mar 27, 2026
XORTX Therapeutics Files Q3 2025 Financial Report — 6-K · Nov 17, 2025 Risk: medium
XORTX Therapeutics Inc. filed a Form 6-K on November 17, 2025, reporting its financial results for the period ending September 30, 2025. The filing includes con
XORTX Therapeutics Files October 2025 6-K Report — 6-K · Oct 31, 2025 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on October 31, 2025, reporting for the month of October 2025. The filing incorporates by reference Exhibits 99.2 and 99
XORTX Therapeutics Files October 2025 Report — 6-K · Oct 29, 2025 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on October 29, 2025, to report its activities for the month of October 2025. The filing indicates that the company is a
XORTX Therapeutics Files 6-K, Incorporates Exhibits — 6-K · Oct 23, 2025 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on October 23, 2025, reporting for the month of October 2025. The filing incorporates by reference Exhibits 99.2, 99.3,
XORTX Therapeutics Files October 2025 6-K Report — 6-K · Oct 21, 2025 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on October 21, 2025, reporting for the month of October 2025. The filing was signed by CEO Allen Davidoff on October 20
XORTX Therapeutics Files October 2025 Report — 6-K · Oct 17, 2025 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on October 17, 2025, to report its activities for the month of October 2025. The filing indicates that the company is a
XORTX Therapeutics Files September 2025 6-K Report — 6-K · Sep 4, 2025 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on September 4, 2025, to report for the month of September 2025. The filing indicates that the company is a foreign pri
XORTX Therapeutics Files September 2025 6-K Report — 6-K · Sep 3, 2025 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on September 3, 2025, to report its activities for the month of September 2025. The filing indicates that the company i
XORTX Therapeutics Files 6-K with Financials — 6-K · Aug 15, 2025 Risk: medium
XORTX Therapeutics Inc. filed a Form 6-K on August 15, 2025, reporting for the period ending June 30, 2025. The filing includes condensed interim consolidated f
XORTX Therapeutics Files August 2025 6-K Report — 6-K · Aug 7, 2025 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on August 7, 2025, to report for the month of August 2025. The filing indicates the company is a foreign private issuer
XORTX Therapeutics Files June 2025 6-K Report — 6-K · Jun 26, 2025 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on June 26, 2025, reporting for the month of June 2025. The filing indicates the company is a foreign private issuer an
XORTX Therapeutics Files May 2025 6-K Report — 6-K · May 19, 2025 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on May 19, 2025, to report its activities for the month of May 2025. The filing indicates that the company is a foreign
XORTX Therapeutics Files Q1 2025 Financial Report — 6-K · May 16, 2025 Risk: medium
XORTX Therapeutics Inc. filed a Form 6-K on May 16, 2025, reporting its financial results for the three months ended March 31, 2025. The filing includes condens
XORTX Therapeutics Files 2024 Annual Report — 20-F · May 12, 2025 Risk: medium
XORTX Therapeutics Inc. filed its annual report on Form 20-F for the fiscal year ending December 31, 2024. The company, incorporated in A1 and headquartered in
XORTX Therapeutics Files April 2025 6-K Report — 6-K · Apr 30, 2025 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on April 30, 2025, reporting for the month of April 2025. The filing indicates that the company is a foreign private is
XORTX Therapeutics Files April 2025 6-K Report — 6-K · Apr 28, 2025 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on April 28, 2025, reporting for the month of April 2025. The filing indicates that the company is a foreign private is
XORTX Therapeutics Files April 2025 6-K Report — 6-K · Apr 18, 2025 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on April 18, 2025, reporting for the month of April 2025. The filing indicates the company is a foreign private issuer
XORTX Therapeutics Files March 2025 6-K with Annual Info — 6-K · Apr 1, 2025 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on April 1, 2025, reporting for the month of March 2025. The filing includes their Annual Information Form for the year
XORTX Therapeutics Files 2024 Financials and MD&A — 6-K · Mar 26, 2025 Risk: medium
XORTX Therapeutics Inc. filed a Form 6-K on March 26, 2025, reporting its consolidated financial statements for the years ended December 31, 2024, 2023, and 202
XORTX Therapeutics Files March 2025 6-K Report — 6-K · Mar 19, 2025 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on March 19, 2025, to report its activities for the month of March 2025. The filing indicates that the company is a for
XORTX Therapeutics Files February 2025 6-K Report — 6-K · Feb 24, 2025 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on February 24, 2025, to report for the month of February 2025. The filing indicates that the company is a foreign priv
XORTX Therapeutics Files January 2025 Report — 6-K · Jan 29, 2025 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on January 29, 2025, to report its activities for the month of January 2025. The filing indicates the company is a fore
XORTX Therapeutics Changes Auditor — 6-K · Jan 22, 2025 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on January 22, 2025, to report a change in its auditor. The company has appointed Smythe LLP as its new auditor, replac
XORTX Therapeutics Files January 2025 6-K Report — 6-K · Jan 21, 2025 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on January 21, 2025, reporting for the month of January 2025. The filing was signed by CEO Allen Davidoff on January 17
XORTX Therapeutics Files January 2025 6-K Report — 6-K · Jan 6, 2025 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on January 6, 2025, to report for the month of January 2025. The filing indicates that the company is a foreign private
XORTX Therapeutics Inc. Files December 2024 Report — 6-K · Dec 19, 2024 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on December 19, 2024, to report its activities for the month of December 2024. The company, headquartered in Calgary, A
XORTX Therapeutics Files December 2024 Report — 6-K · Dec 12, 2024 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on December 12, 2024, to report its activities for the month of December 2024. The filing indicates that the company is
XORTX Therapeutics Files Q3 2024 Financial Report — 6-K · Nov 15, 2024 Risk: medium
XORTX Therapeutics Inc. filed a Form 6-K on November 15, 2024, reporting its financial results for the nine months ended September 30, 2024. The filing includes
XORTX Therapeutics Files October 2024 6-K Report — 6-K · Oct 24, 2024 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on October 24, 2024, to report its activities for the month of October 2024. The filing indicates that the company is a
XORTX Therapeutics Files October 2024 6-K Report — 6-K · Oct 18, 2024 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on October 18, 2024, to report its activities for the month of October 2024. The filing indicates that the company is a
XORTX Therapeutics Files 6-K, Incorporates Exhibits — 6-K · Oct 18, 2024 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on October 18, 2024, incorporating by reference Exhibits 5.1 and 5.2 into its existing Form F-3 Registration Statement
XORTX Therapeutics Files October 2024 Report — 6-K · Oct 17, 2024 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on October 17, 2024, to report its activities for the month of October 2024. The filing indicates that the company is a
XORTX Therapeutics Files October 2024 Report — 6-K · Oct 9, 2024 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on October 9, 2024, to report its activities for the month of October 2024. The filing indicates the company is a forei
XORTX Therapeutics Files 6-K Report — 6-K · Sep 13, 2024 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on September 13, 2024. The report indicates the company is a foreign private issuer and will file its annual reports un
XORTX Therapeutics Files September 2024 6-K Report — 6-K · Sep 6, 2024 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on September 6, 2024, reporting for the month of September 2024. The company, incorporated in Alberta, Canada, is invol
XORTX Therapeutics Files September 2024 Report — 6-K · Sep 4, 2024 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on September 3, 2024, to report its activities for the month of September 2024. The filing indicates that the company i
XORTX Therapeutics Files August 2024 Report — 6-K · Aug 29, 2024 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on August 29, 2024, to report its activities for the month of August 2024. The filing indicates that the company is a f
XORTX Therapeutics Files August 2024 Report — 6-K · Aug 23, 2024 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on August 23, 2024, to report its activities for the month of August 2024. The filing indicates that the company is a f
XORTX Therapeutics Files August 2024 Report — 6-K · Aug 22, 2024 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on August 22, 2024, reporting for the month of August 2024. The filing includes notices and information circulars relat
XORTX Therapeutics Files August 2024 Report — 6-K · Aug 20, 2024 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on August 20, 2024, to report its activities for the month of August 2024. The filing indicates that the company is a f
XORTX Therapeutics Files 6-K with Q2 2024 Financials — 6-K · Aug 15, 2024 Risk: medium
XORTX Therapeutics Inc. filed a Form 6-K on August 15, 2024, reporting its financial results for the period ending June 30, 2024. The filing includes condensed
XORTX Therapeutics Files June 2024 6-K with Executive Compensation Data — 6-K · Jul 1, 2024 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on June 28, 2024, reporting for the month of June 2024. The filing includes Exhibit 99.1, which is a Statement of Execu
XORTX Therapeutics Files June 2024 Report (6-K) — 6-K · Jun 12, 2024 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on June 12, 2024, to report its activities for the month of June 2024. The filing indicates that the company is a forei
XORTX Therapeutics Files June 2024 Report — 6-K · Jun 4, 2024 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on June 4, 2024, to report its activities for the month of June 2024. The filing indicates that the company is a foreig
XORTX Therapeutics Files 6-K Report — 6-K · May 20, 2024 Risk: low
XORTX Therapeutics Inc. filed a Form 6-K on May 17, 2024, to report its activities for the month of May 2024. The filing confirms that the company is a foreign
XORTX Therapeutics Files Q1 2024 Financial Results — 6-K · May 17, 2024 Risk: medium
XORTX Therapeutics Inc. filed a Form 6-K on May 17, 2024, reporting its financial results for the three months ended March 31, 2024. The filing includes condens

Frequently Asked Questions

What are the latest SEC filings for Xortx Therapeutics INC. (XRTX)?

Xortx Therapeutics INC. has 50 recent SEC filings from May 2024 to Apr 2026, including 49 6-K, 1 20-F. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of XRTX filings?

Across 50 filings, the sentiment breakdown is: 50 neutral. The dominant sentiment is neutral.

Where can I find Xortx Therapeutics INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Xortx Therapeutics INC. (XRTX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.